Halozyme Therapeutics Files 8-K
Ticker: HALO · Form: 8-K · Filed: Nov 7, 2025 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | 8-K |
| Filed Date | Nov 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $650.0 million, $100.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: HALO
TL;DR
HALO filed an 8-K, looks like routine stuff, no major news yet.
AI Summary
On November 6, 2025, Halozyme Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific material events detailed in the provided text. The report was filed on November 7, 2025.
Why It Matters
This 8-K filing indicates routine corporate reporting by Halozyme Therapeutics, Inc., with no immediate material events disclosed in the excerpt.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no disclosed material events, suggesting low immediate risk.
Key Players & Entities
- HALOZYME THERAPEUTICS, INC. (company) — Registrant
- November 6, 2025 (date) — Earliest Event Reported
- November 7, 2025 (date) — Filing Date
- 12390 El Camino Real (location) — Principal Executive Offices
- San Diego (location) — City of Principal Executive Offices
- California (location) — State of Principal Executive Offices
- 92130 (location) — Zip Code of Principal Executive Offices
- 858-794-8889 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" for Halozyme Therapeutics, Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 6, 2025.
On what date was this 8-K filed with the SEC?
This 8-K was filed with the SEC on November 7, 2025.
What is the principal executive office address for Halozyme Therapeutics, Inc.?
The principal executive office address for Halozyme Therapeutics, Inc. is 12390 El Camino Real, San Diego, California, 92130.
Does the filing detail any specific material events or transactions?
Based on the provided text, no specific material events or transactions are detailed; the filing primarily indicates "Other Events" and "Financial Statements and Exhibits."
Filing Stats: 565 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-11-07 08:02:52
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market
- $650.0 million — nouncing the pricing of its offering of $650.0 million aggregate principal amount of convertib
- $100.0 million — chasers to purchase up to an additional $100.0 million aggregate principal amount of the 2031
Filing Documents
- halo-20251106.htm (8-K) — 33KB
- ex991halo-pricingpressrele.htm (EX-99.1) — 25KB
- halo-20251106_g1.jpg (GRAPHIC) — 15KB
- image_1a.jpg (GRAPHIC) — 5KB
- 0001159036-25-000049.txt ( ) — 212KB
- halo-20251106.xsd (EX-101.SCH) — 2KB
- halo-20251106_lab.xml (EX-101.LAB) — 21KB
- halo-20251106_pre.xml (EX-101.PRE) — 12KB
- halo-20251106_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On November 6, 2025, Halozyme Therapeutics, Inc. (the "Company") issued a press release announcing the pricing of its offering of $650.0 million aggregate principal amount of convertible senior notes due 2031 (the "2031 Notes") and $650.0 million aggregate principal amount of convertible senior notes due 2032 (the "2032 Notes" and, together with the 2031 Notes, the "Convertible Notes"). The Company also granted a 13-day option to the initial purchasers to purchase up to an additional $100.0 million aggregate principal amount of the 2031 Notes and up to an additional $100.0 million aggregate principal amount of the 2032 Notes. The Convertible Notes are being offered and sold only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document Description 99.1 Press release, dated November 6, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). *Certain schedules omitted pursuant to Item 601(a)(5) of Regulation S-K. Halozyme agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HALOZYME THERAPEUTICS, INC. Date: November 7, 2025 By: /s/ Nicole LaBrosse Name: Nicole LaBrosse Title: Senior Vice President, Chief Financial Officer